These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33344548)

  • 21. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
    Chen CY; Wu VC; Lin CJ; Lin CS; Pan CF; Chen HH; Lin YF; Huang TM; Chen L; Wu CJ;
    Mayo Clin Proc; 2018 Dec; 93(12):1760-1774. PubMed ID: 30343892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study.
    Chen HH; Hsieh MC; Ho CW; Chen CC; Hsu SP; Lin CL; Kao CH
    Ann Palliat Med; 2020 Sep; 9(5):2817-2825. PubMed ID: 32787376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
    Torrecillas-Baena B; Gálvez-Moreno MÁ; Quesada-Gómez JM; Dorado G; Casado-Díaz A
    Stem Cell Rev Rep; 2022 Jan; 18(1):56-76. PubMed ID: 34677817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DPP4 inhibitor reinforces cell junction proteins in mouse model of short bowel syndrome.
    Sueyoshi R; Miyahara K; Nakazawa-Tanaka N; Fujiwara N; Ochi T; Yamataka A
    Pediatr Surg Int; 2020 Jan; 36(1):49-55. PubMed ID: 31576468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Lee HF; Chuang C; Li PR; Yeh YH; Chan YH; See LC
    Diabetol Metab Syndr; 2023 Jan; 15(1):8. PubMed ID: 36653811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression.
    Kang EY; Kang C; Wu WC; Sun CC; Chen KJ; Lai CC; Chen TH; Hwang YS
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34203446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019.
    Zhang J; Kong W; Xia P; Xu Y; Li L; Li Q; Yang L; Wei Q; Wang H; Li H; Zheng J; Sun H; Xia W; Liu G; Zhong X; Qiu K; Li Y; Wang H; Wang Y; Song X; Liu H; Xiong S; Liu Y; Cui Z; Hu Y; Chen L; Pan A; Zeng T
    Front Endocrinol (Lausanne); 2020; 11():525. PubMed ID: 32754119
    [No Abstract]   [Full Text] [Related]  

  • 30. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study.
    Lin YH; Huang YY; Wu YL; Lin CW; Chen PC; Chang CJ; Hsieh SH; Sun JH; Chen ST; Lin CH
    Diabetol Metab Syndr; 2018; 10():75. PubMed ID: 30349614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.
    Shah C; Hong YR; Bishnoi R; Ali A; Skelton WP; Dang LH; Huo J; Dang NH
    Front Oncol; 2020; 10():405. PubMed ID: 32296640
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
    Chen L; Zhang X; Zhang L; Zheng D
    Diabetes Metab Syndr Obes; 2020; 13():3507-3518. PubMed ID: 33116702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients.
    Wu B; Zhou JH; Wang WX; Yang HL; Xia M; Zhang BH; She ZG; Li HL
    Chin Med Sci J; 2021 Mar; 36(1):17-26. PubMed ID: 33853705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study.
    Park T; Bresnahan M; Griggs SK; Chen J; Cho AH; Gousse Y; Feinglos M
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100022. PubMed ID: 35481118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review.
    Popovic DS; Papanas N; Pantea Stoian A; Rizvi AA; Janez A; Rizzo M
    Diabetes Ther; 2021 Dec; 12(12):3037-3054. PubMed ID: 34699021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19.
    Kifle ZD; Woldeyohanin AE; Demeke CA
    Metabol Open; 2021 Dec; 12():100134. PubMed ID: 34661092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitor treatment could decrease
    Chen HH; Chen CC; Ho CW; Hsieh MC; Hsu SP; Lin CL; Kao CH
    Postgrad Med; 2020 Nov; 132(8):714-719. PubMed ID: 32633173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
    Bukvić Mokos Z; Petković M; Balić A; Marinović B
    Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.